US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

32.13

+1.545.02%

Volume:909.62K

Turnover:28.97M

Market Cap:1.85B

PE:17.93

High:32.30

Open:30.77

Low:30.76

Close:30.59

52wk High:79.18

52wk Low:27.09

Shares:57.44M

Float Shares:38.70M

Volume Ratio:0.81

T/O Rate:2.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):1.79

EPS(LYR):1.64

ROE:29.74%

ROA:9.38%

PB:4.85

PE(LYR):19.55

Loading ...

Overview Company News Filings

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

KeyBanc Sticks to Their Buy Rating for ODDITY Tech Ltd. Class A (ODD)

ODDITY to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Oddity Tech (ODD) Is Down 8.7% After Il Makiage Slowdown Jitters And MethodIQ Spend Concerns

Simply Wall St.

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027

Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

Odd Burger Warns of Imminent Cease Trade Order Over Delayed Annual Filings

Quoin announces submission to Japanese MHLW for ODD for QRX003

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

LEADS BIOLABS-B (09887): Vilisin™ Granted Orphan Drug Designation (ODD) by European Commission for Treatment of Extrapulmonary Neuroendocrine Carcinoma

Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen

Insider-Favored Growth Stocks To Consider In January 2026

Simply Wall St.

Assessing Oddity Tech (ODD) Valuation After Analyst Praise And METHODIQ Skincare Launch

Simply Wall St.

Odd Burger Delays Annual Filings After Financing Default Triggers Liquidity Crunch

ODDITY Tech Secures Expanded $350 Million Credit Facilities to Fund Growth

Oddity Tech Ltd: Co Has Entered Into Amendments to Existing Agreements With Syndicate of Banks to Secure Credit Facilities for Total of $350 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ODD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":32.125,"timestamp":1771614344966,"preClose":30.59,"halted":0,"volume":909615,"delay":0,"changeRate":0.050179797319385426,"floatShares":38696732,"shares":57438900,"eps":1.791771,"marketStatus":"Trading","change":1.535,"latestTime":"02-20 14:05:45 EST","open":30.77,"high":32.3,"low":30.76,"amount":28970047.97358,"amplitude":0.050343,"askPrice":32.16,"askSize":200,"bidPrice":32.09,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.791771,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771621200000},"marketStatusCode":2,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":30.59,"preHourTrading":{"tag":"盘前","latestPrice":30.89,"preClose":30.59,"latestTime":"09:19 EST","volume":1837,"amount":57068.03993,"timestamp":1771597197394,"change":0.3,"changeRate":0.009807,"amplitude":0.055247},"postHourTrading":{"tag":"盘后","latestPrice":30.88,"preClose":30.59,"latestTime":"19:52 EST","volume":11325,"amount":346834.19,"timestamp":1771548729523,"change":0.29,"changeRate":0.00948,"amplitude":0.014057},"volumeRatio":0.81125,"impliedVol":1.0557,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","floatShares":38696732,"roa":"9.38%","roe":"29.74%","lyrEps":1.642966,"volumeRatio":0.81125,"shares":57438900,"dividePrice":0,"high":32.3,"amplitude":0.050343,"preClose":30.59,"low":30.76,"week52Low":27.09,"pbRate":"4.85","psRate":"2.36","week52High":79.1804,"institutionHeld":0,"latestPrice":32.125,"committee":-0.333333,"eps":1.791771,"divideRate":0,"volume":909615,"delay":0,"ttmEps":1.791771,"open":30.77,"prevYearClose":40.18,"prevWeekClose":28.08,"prevMonthClose":32.84,"prevQuarterClose":40.18,"fiveDayClose":27.61,"twentyDayClose":35.04,"sixtyDayClose":37.7,"earningDate":1771948800000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODD\",params:#limit:5,,,undefined,":[{"date":"2026-02-25","symbol":"ODD","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772010000000,"name":null,"time":"Pre-Market","dateTimestamp":1771995600000,"actualEps":null},{"market":"US","date":"2025-11-19","symbol":"ODD","fiscalQuarterEnding":"2025/09","expectedEps":0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763528400000,"reportTimeType":"post","actualEps":0.28},{"market":"US","date":"2025-08-04","symbol":"ODD","fiscalQuarterEnding":"2025/06","expectedEps":0.79,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754280000000,"reportTimeType":"post","actualEps":0.76},{"market":"US","date":"2025-04-29","symbol":"ODD","fiscalQuarterEnding":"2025/03","expectedEps":0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745899200000,"reportTimeType":"post","actualEps":0.63},{"market":"US","date":"2025-02-25","symbol":"ODD","fiscalQuarterEnding":"2024/12","expectedEps":0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740459600000,"reportTimeType":"post","actualEps":0.06}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.5455,"hold":0.2727,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1758690000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODD","date":"2026-02-19","current":17.072494,"percent":0.009404,"low":14.396348,"twenty":24.010889,"median":30.43083,"eighty":38.911687,"high":144.174884,"avg":32.813062,"sd":15.689661,"marketCap":1722017412},"quantilePoints":[{"date":"2023-07-21","current":130.121737,"twenty":124.979326,"median":126.90773,"eighty":128.836134,"marketCap":2827285100},{"date":"2023-07-28","current":127.857619,"twenty":126.192061,"median":128.560276,"eighty":129.606455,"marketCap":2778090339},{"date":"2023-08-04","current":144.174884,"twenty":128.138682,"median":130.121737,"eighty":138.668132,"marketCap":3132631890},{"date":"2023-08-11","current":59.921033,"twenty":128.138682,"median":131.59899,"eighty":138.150305,"marketCap":3096718967},{"date":"2023-08-18","current":49.805463,"twenty":52.028567,"median":129.262933,"eighty":135.506534,"marketCap":2573946329},{"date":"2023-08-25","current":45.155781,"twenty":48.598524,"median":91.807378,"eighty":132.13135,"marketCap":2333650744},{"date":"2023-09-01","current":45.716381,"twenty":47.266275,"median":50.709145,"eighty":131.711973,"marketCap":2362622552},{"date":"2023-09-08","current":40.286255,"twenty":46.134083,"median":49.805463,"eighty":131.410685,"marketCap":2081993665},{"date":"2023-09-15","current":40.648996,"twenty":43.649855,"median":48.206104,"eighty":130.121737,"marketCap":2100740129},{"date":"2023-09-22","current":30.701094,"twenty":40.692965,"median":47.574055,"eighty":129.262933,"marketCap":1586632553},{"date":"2023-09-29","current":31.151773,"twenty":36.878686,"median":46.562777,"eighty":127.857619,"marketCap":1609923614},{"date":"2023-10-06","current":28.491671,"twenty":32.503808,"median":45.749357,"eighty":123.693723,"marketCap":1472449544},{"date":"2023-10-13","current":31.976185,"twenty":32.503808,"median":44.402818,"eighty":59.921033,"marketCap":1652529215},{"date":"2023-10-20","current":29.832714,"twenty":31.459553,"median":41.803173,"eighty":57.306257,"marketCap":1541754654},{"date":"2023-10-27","current":29.832714,"twenty":31.15617,"median":40.714949,"eighty":54.667412,"marketCap":1541754654},{"date":"2023-11-03","current":29.678824,"twenty":30.355941,"median":40.467625,"eighty":50.479578,"marketCap":1533801609},{"date":"2023-11-10","current":30.298177,"twenty":30.305454,"median":36.878686,"eighty":50.003322,"marketCap":1598562121},{"date":"2023-11-17","current":37.221321,"twenty":30.355941,"median":36.411519,"eighty":49.783479,"marketCap":1963834134},{"date":"2023-11-24","current":37.016749,"twenty":30.445709,"median":37.119035,"eighty":49.462508,"marketCap":1953040715},{"date":"2023-12-01","current":36.693741,"twenty":30.5941,"median":37.016749,"eighty":48.26876,"marketCap":1935998475},{"date":"2023-12-08","current":40.591374,"twenty":30.734071,"median":37.17287,"eighty":48.041138,"marketCap":2141641505},{"date":"2023-12-15","current":46.060981,"twenty":30.923136,"median":37.910406,"eighty":47.753992,"marketCap":2430223438},{"date":"2023-12-22","current":50.712301,"twenty":31.153971,"median":38.59949,"eighty":48.041138,"marketCap":2675631695},{"date":"2023-12-29","current":50.884572,"twenty":31.160567,"median":38.868664,"eighty":49.761494,"marketCap":2684720890},{"date":"2024-01-05","current":46.7716,"twenty":31.28148,"median":39.765881,"eighty":49.183424,"marketCap":2467716366},{"date":"2024-01-12","current":46.965405,"twenty":31.46395,"median":40.526773,"eighty":48.323896,"marketCap":2477941710},{"date":"2024-01-19","current":45.899477,"twenty":31.472743,"median":40.645209,"eighty":48.306372,"marketCap":2421702318},{"date":"2024-01-26","current":45.684138,"twenty":31.580467,"median":40.703957,"eighty":48.306372,"marketCap":2410340824},{"date":"2024-02-02","current":45.156558,"twenty":31.989432,"median":42.12028,"eighty":48.252127,"marketCap":2382505165},{"date":"2024-02-09","current":48.246671,"twenty":32.113484,"median":43.346019,"eighty":48.217673,"marketCap":2545542596},{"date":"2024-02-16","current":46.125583,"twenty":32.418946,"median":44.467474,"eighty":48.217673,"marketCap":2433631886},{"date":"2024-02-23","current":42.389454,"twenty":32.503808,"median":43.451996,"eighty":48.101679,"marketCap":2236509975},{"date":"2024-03-01","current":45.414965,"twenty":32.586249,"median":43.346019,"eighty":47.880595,"marketCap":2396138958},{"date":"2024-03-08","current":42.187798,"twenty":32.646706,"median":43.451996,"eighty":47.880595,"marketCap":2469420590},{"date":"2024-03-15","current":43.718187,"twenty":32.976471,"median":43.684021,"eighty":47.798976,"marketCap":2559000375},{"date":"2024-03-22","current":43.038127,"twenty":33.910804,"median":43.451996,"eighty":47.751391,"marketCap":2519193702},{"date":"2024-03-28","current":41.755726,"twenty":34.121582,"median":43.229275,"eighty":47.682483,"marketCap":2444129691},{"date":"2024-04-05","current":35.33401,"twenty":34.429566,"median":43.074483,"eighty":47.592295,"marketCap":2068240969},{"date":"2024-04-12","current":35.168853,"twenty":35.003425,"median":42.938568,"eighty":47.491972,"marketCap":2058573635},{"date":"2024-04-19","current":32.672059,"twenty":33.859301,"median":42.736957,"eighty":47.44561,"marketCap":1912426280},{"date":"2024-04-26","current":30.816464,"twenty":32.666988,"median":42.389454,"eighty":47.239294,"marketCap":1803810931},{"date":"2024-05-03","current":32.701204,"twenty":32.521826,"median":42.280345,"eighty":47.139393,"marketCap":1914132280},{"date":"2024-05-10","current":30.051334,"twenty":32.188614,"median":42.12028,"eighty":47.109682,"marketCap":2161502316},{"date":"2024-05-17","current":34.470881,"twenty":32.029175,"median":41.880975,"eighty":47.036466,"marketCap":2479387030},{"date":"2024-05-24","current":28.991908,"twenty":31.962852,"median":41.668069,"eighty":46.979437,"marketCap":2085300972},{"date":"2024-05-31","current":28.39104,"twenty":31.618936,"median":40.692965,"eighty":46.967038,"marketCap":2042082299},{"date":"2024-06-07","current":35.032218,"twenty":31.466148,"median":40.618291,"eighty":46.952485,"marketCap":2519762369},{"date":"2024-06-14","current":31.434913,"twenty":31.466148,"median":40.526773,"eighty":46.846969,"marketCap":2261018998},{"date":"2024-06-21","current":31.17401,"twenty":31.40776,"median":40.286255,"eighty":46.77806,"marketCap":2242252995},{"date":"2024-06-28","current":31.039605,"twenty":31.15617,"median":39.116208,"eighty":46.676851,"marketCap":2232585660},{"date":"2024-07-05","current":32.549682,"twenty":31.153971,"median":38.825596,"eighty":46.51104,"marketCap":2341201009},{"date":"2024-07-12","current":33.300768,"twenty":31.165014,"median":38.233414,"eighty":46.411983,"marketCap":2395224351},{"date":"2024-07-19","current":31.719535,"twenty":31.193823,"median":37.851188,"eighty":46.379683,"marketCap":2281491001},{"date":"2024-07-26","current":32.889648,"twenty":31.177172,"median":37.124419,"eighty":46.315081,"marketCap":2365653680},{"date":"2024-08-02","current":30.43083,"twenty":31.177172,"median":37.016749,"eighty":46.269497,"marketCap":2188798320},{"date":"2024-08-09","current":24.621128,"twenty":31.077829,"median":36.878686,"eighty":46.15167,"marketCap":2152403648},{"date":"2024-08-16","current":25.909103,"twenty":30.914687,"median":36.319047,"eighty":46.132383,"marketCap":2264999665},{"date":"2024-08-23","current":24.744722,"twenty":30.826367,"median":35.664326,"eighty":46.112663,"marketCap":2163208317},{"date":"2024-08-30","current":23.938111,"twenty":30.576415,"median":35.479654,"eighty":46.043754,"marketCap":2092693640},{"date":"2024-09-06","current":21.999645,"twenty":30.415298,"median":35.251431,"eighty":45.974846,"marketCap":1923230948},{"date":"2024-09-13","current":22.858294,"twenty":30.138302,"median":35.032218,"eighty":45.974846,"marketCap":1998294959},{"date":"2024-09-20","current":23.144511,"twenty":29.832714,"median":34.577614,"eighty":45.899477,"marketCap":2023316296},{"date":"2024-09-27","current":25.837549,"twenty":29.733784,"median":34.493388,"eighty":45.749357,"marketCap":2258744331},{"date":"2024-10-04","current":26.907033,"twenty":29.206161,"median":34.203986,"eighty":45.716381,"marketCap":2352239691},{"date":"2024-10-11","current":26.632604,"twenty":28.857503,"median":34.05976,"eighty":45.700078,"marketCap":2328248903},{"date":"2024-10-18","current":26.737148,"twenty":28.675661,"median":33.782046,"eighty":45.684138,"marketCap":2337388251},{"date":"2024-10-25","current":24.829219,"twenty":28.39104,"median":33.498422,"eighty":45.587236,"marketCap":2170595150},{"date":"2024-11-01","current":24.874957,"twenty":27.774359,"median":33.138619,"eighty":45.414965,"marketCap":2174593614},{"date":"2024-11-08","current":25.903059,"twenty":26.907033,"median":32.701204,"eighty":45.328829,"marketCap":2624135294},{"date":"2024-11-15","current":22.412856,"twenty":26.554196,"median":32.64481,"eighty":45.156558,"marketCap":2270556768},{"date":"2024-11-22","current":25.688798,"twenty":26.266873,"median":32.549682,"eighty":45.155781,"marketCap":2602429343},{"date":"2024-11-29","current":26.196259,"twenty":26.231703,"median":32.526331,"eighty":45.078881,"marketCap":2653838175},{"date":"2024-12-06","current":27.019473,"twenty":26.102043,"median":32.510933,"eighty":44.930453,"marketCap":2737234726},{"date":"2024-12-13","current":27.882156,"twenty":26.129486,"median":32.397731,"eighty":44.829243,"marketCap":2824629741},{"date":"2024-12-20","current":24.673876,"twenty":26.102043,"median":32.284642,"eighty":44.80743,"marketCap":2499611678},{"date":"2024-12-27","current":24.555468,"twenty":26.074468,"median":32.122117,"eighty":44.68052,"marketCap":2487616283},{"date":"2025-01-03","current":24.036731,"twenty":26.028044,"median":31.982415,"eighty":44.572573,"marketCap":2435065032},{"date":"2025-01-10","current":24.916329,"twenty":25.91918,"median":31.969518,"eighty":44.533395,"marketCap":2524173675},{"date":"2025-01-17","current":25.299744,"twenty":25.850651,"median":31.948814,"eighty":44.510542,"marketCap":2563015904},{"date":"2025-01-24","current":24.983991,"twenty":25.688798,"median":31.719535,"eighty":44.467474,"marketCap":2531028186},{"date":"2025-01-31","current":26.906704,"twenty":25.660605,"median":31.631647,"eighty":44.252135,"marketCap":2725810541},{"date":"2025-02-07","current":24.025454,"twenty":25.660605,"median":31.600943,"eighty":44.067933,"marketCap":2433922614},{"date":"2025-02-14","current":24.245353,"twenty":25.528357,"median":31.476041,"eighty":43.718187,"marketCap":2456199775},{"date":"2025-02-21","current":24.809199,"twenty":25.393274,"median":31.447233,"eighty":43.663521,"marketCap":2513320700},{"date":"2025-02-28","current":26.194867,"twenty":25.287339,"median":31.363758,"eighty":43.611255,"marketCap":2658543217},{"date":"2025-03-07","current":24.561126,"twenty":25.149762,"median":31.267028,"eighty":43.481918,"marketCap":2492733193},{"date":"2025-03-14","current":25.259729,"twenty":25.127573,"median":31.17401,"eighty":43.282433,"marketCap":2563635122},{"date":"2025-03-21","current":23.829518,"twenty":25.089994,"median":31.105558,"eighty":43.231428,"marketCap":2418481566},{"date":"2025-03-28","current":23.620487,"twenty":25.062794,"median":30.968449,"eighty":43.177394,"marketCap":2397266815},{"date":"2025-04-04","current":20.886583,"twenty":24.97973,"median":30.909153,"eighty":43.121556,"marketCap":2119800209},{"date":"2025-04-11","current":22.872376,"twenty":24.935811,"median":30.865977,"eighty":43.052669,"marketCap":2321340339},{"date":"2025-04-17","current":23.075906,"twenty":24.876099,"median":30.80242,"eighty":42.991494,"marketCap":2341996807},{"date":"2025-04-25","current":24.341093,"twenty":24.812177,"median":30.590011,"eighty":42.947303,"marketCap":2470401876},{"date":"2025-05-02","current":33.211688,"twenty":24.800183,"median":30.612672,"eighty":42.912727,"marketCap":3531697688},{"date":"2025-05-09","current":37.275211,"twenty":24.812177,"median":30.809442,"eighty":42.852836,"marketCap":3963808661},{"date":"2025-05-16","current":33.075187,"twenty":24.823197,"median":30.881482,"eighty":42.719469,"marketCap":3517182333},{"date":"2025-05-23","current":36.009954,"twenty":24.840888,"median":30.917059,"eighty":42.57047,"marketCap":3829262479},{"date":"2025-05-30","current":37.968215,"twenty":24.859184,"median":31.004027,"eighty":42.466444,"marketCap":4037502005},{"date":"2025-06-06","current":40.472479,"twenty":24.875718,"median":31.151773,"eighty":42.376534,"marketCap":4303802953},{"date":"2025-06-13","current":38.84497,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"marketCap":4130735251},{"date":"2025-06-20","current":36.618957,"twenty":24.907308,"median":31.267028,"eighty":42.321149,"marketCap":3894023297},{"date":"2025-06-27","current":37.637463,"twenty":24.9212,"median":31.363758,"eighty":42.207431,"marketCap":4002330181},{"date":"2025-07-03","current":39.798375,"twenty":24.940682,"median":31.434913,"eighty":42.187798,"marketCap":4232119427},{"date":"2025-07-11","current":38.424967,"twenty":24.946182,"median":31.476041,"eighty":42.12028,"marketCap":4086072618},{"date":"2025-07-18","current":37.17546,"twenty":24.957184,"median":31.58513,"eighty":42.056896,"marketCap":3953201285},{"date":"2025-07-25","current":36.450956,"twenty":24.962685,"median":31.617964,"eighty":41.958776,"marketCap":3876158244},{"date":"2025-08-01","current":36.786958,"twenty":24.983991,"median":31.719535,"eighty":41.803173,"marketCap":3911888350},{"date":"2025-08-08","current":29.269388,"twenty":24.988656,"median":31.680004,"eighty":41.755726,"marketCap":3223525522},{"date":"2025-08-15","current":29.576073,"twenty":25.039696,"median":31.613107,"eighty":41.668069,"marketCap":3257301638},{"date":"2025-08-22","current":30.491058,"twenty":25.068568,"median":31.584654,"eighty":40.714949,"marketCap":3358071703},{"date":"2025-08-29","current":30.947283,"twenty":25.079845,"median":31.470545,"eighty":40.692965,"marketCap":3408317165},{"date":"2025-09-05","current":31.494754,"twenty":25.083205,"median":31.459553,"eighty":40.65779,"marketCap":3468611719},{"date":"2025-09-12","current":31.935772,"twenty":25.085195,"median":31.488146,"eighty":40.645966,"marketCap":3517182333},{"date":"2025-09-19","current":31.793835,"twenty":25.089994,"median":31.584179,"eighty":40.616226,"marketCap":3501550411},{"date":"2025-09-26","current":29.994279,"twenty":25.105422,"median":31.49222,"eighty":40.594895,"marketCap":3303359978},{"date":"2025-10-03","current":30.739447,"twenty":25.114201,"median":31.481537,"eighty":40.590201,"marketCap":3385427566},{"date":"2025-10-10","current":26.927161,"twenty":25.127573,"median":31.451808,"eighty":40.571566,"marketCap":2965569012},{"date":"2025-10-17","current":26.01968,"twenty":25.135101,"median":31.389658,"eighty":40.56278,"marketCap":2865625373},{"date":"2025-10-24","current":24.575011,"twenty":25.135101,"median":31.29655,"eighty":40.533764,"marketCap":2706519695},{"date":"2025-10-31","current":22.697464,"twenty":25.089994,"median":31.260978,"eighty":40.483338,"marketCap":2499739752},{"date":"2025-11-07","current":20.840778,"twenty":25.062794,"median":31.168388,"eighty":40.3235,"marketCap":2295257365},{"date":"2025-11-14","current":21.127625,"twenty":24.961585,"median":31.125566,"eighty":40.286255,"marketCap":2326848745},{"date":"2025-11-21","current":20.632506,"twenty":24.914074,"median":31.026394,"eighty":40.195833,"marketCap":2272856204},{"date":"2025-11-28","current":22.556538,"twenty":24.864441,"median":30.973992,"eighty":40.067661,"marketCap":2484805645},{"date":"2025-12-05","current":23.453377,"twenty":24.800183,"median":30.947283,"eighty":39.942199,"marketCap":2583600507},{"date":"2025-12-12","current":23.171811,"twenty":24.744189,"median":30.91898,"eighty":39.889726,"marketCap":2552583516},{"date":"2025-12-19","current":22.108118,"twenty":24.698354,"median":30.913106,"eighty":39.830715,"marketCap":2435408215},{"date":"2025-12-26","current":21.97255,"twenty":24.603474,"median":30.881482,"eighty":39.790815,"marketCap":2420474108},{"date":"2026-01-02","current":20.950571,"twenty":24.5566,"median":30.865977,"eighty":39.747975,"marketCap":2307893917},{"date":"2026-01-09","current":20.079803,"twenty":24.511489,"median":30.793745,"eighty":39.569474,"marketCap":2211970999},{"date":"2026-01-16","current":18.426908,"twenty":24.453976,"median":30.739447,"eighty":39.33668,"marketCap":2029889771},{"date":"2026-01-23","current":18.270483,"twenty":24.345533,"median":30.673548,"eighty":39.245507,"marketCap":2012658109},{"date":"2026-01-30","current":17.535284,"twenty":24.313015,"median":30.590011,"eighty":39.075971,"marketCap":1931669298},{"date":"2026-02-06","current":15.001193,"twenty":24.204717,"median":30.513869,"eighty":38.986908,"marketCap":1652516376},{"date":"2026-02-13","current":14.396348,"twenty":24.048695,"median":30.485989,"eighty":38.976221,"marketCap":1585887283},{"date":"2026-02-19","current":15.632108,"twenty":24.010889,"median":30.43083,"eighty":38.911687,"marketCap":1722017412}],"updateTime":1771595400105},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612781267","title":"Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2612781267","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612781267?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:50","pubTimestamp":1771595400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Feb.  20, 2026  (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/20/3241937/0/en/Senti-Bio-Participates-in-Cell-Gene-Live-Event-Highlighting-Cutting-Edge-Technologies-Advancing-Cell-Therapy-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","IE0009354923.USD","BK4183"],"gpt_icon":0},{"id":"2612826802","title":"KeyBanc Sticks to Their Buy Rating for ODDITY Tech Ltd. Class A (ODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612826802","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612826802?lang=en_us&edition=fundamental","pubTime":"2026-02-20 17:05","pubTimestamp":1771578336,"startTime":"0","endTime":"0","summary":"In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on ODDITY Tech Ltd. Class A, with a price target of $50.00. Schoe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/keybanc-sticks-to-their-buy-rating-for-oddity-tech-ltd-class-a-odd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/keybanc-sticks-to-their-buy-rating-for-oddity-tech-ltd-class-a-odd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2612429058","title":"ODDITY to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612429058","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612429058?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:05","pubTimestamp":1771448700,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb.  18, 2026  (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (“ODDITY”) (NASDAQ: ODD), today announced that it will release its fourth quarter and full year 2025 financial results before the market ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240629/0/en/ODDITY-to-Announce-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-25-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2610958715","title":"Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610958715","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610958715?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:35","pubTimestamp":1770816900,"startTime":"0","endTime":"0","summary":"Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 int","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/11/3236291/0/en/Senti-Biosciences-Completes-Enrollment-in-Phase-1-Clinical-Trial-of-SENTI-202-for-the-Treatment-of-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-R-R-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ASH","ODD","BK4109","LU2463526074.USD","IE0009354923.USD"],"gpt_icon":0},{"id":"2610695598","title":"Oddity Tech (ODD) Is Down 8.7% After Il Makiage Slowdown Jitters And MethodIQ Spend Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2610695598","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610695598?lang=en_us&edition=fundamental","pubTime":"2026-02-10 07:26","pubTimestamp":1770679608,"startTime":"0","endTime":"0","summary":"In its Q4 2025 investor letter, Baron Small Cap Fund cited Oddity Tech as a leading detractor, pointing to investor concerns about potential category weakness and signs of a slowdown at flagship brand Il Makiage based on industry commentary and credit card data. \nAt the same time, Oddity Tech’s upcoming launch of its third platform, MethodIQ, introduces meaningful upfront marketing costs and added uncertainty to its financial profile. \nWe’ll now examine how concerns about Il Makiage’s...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-odd-is-down-87-after-il-makiage-slowdown-jitters","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-odd-is-down-87-after-il-makiage-slowdown-jitters","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AI","BK4023","BK4183","IE0009354923.USD","ODD","BK4551","BK4528","BK4543","BK4585","BK4587","BK4588"],"gpt_icon":0},{"id":"2608361393","title":"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2608361393","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608361393?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:05","pubTimestamp":1770206700,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “C","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3231919/0/en/Unicycive-Therapeutics-to-Participate-in-a-Fireside-Chat-at-Guggenheim-s-Emerging-Outlook-Biotech-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4585","BK4139","BK4211","BK4539","ODD","LABU","UNCY","IE0009354923.USD","BK4588","SMMF"],"gpt_icon":0},{"id":"2607841680","title":"Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission","url":"https://stock-news.laohu8.com/highlight/detail?id=2607841680","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607841680?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:05","pubTimestamp":1769688300,"startTime":"0","endTime":"0","summary":"DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan.  29, 2026  (GLOBE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/29/3228435/0/en/Unicycive-Therapeutics-Announces-FDA-Acceptance-of-Oxylanthanum-Carbonate-OLC-New-Drug-Application-NDA-Resubmission.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU2237443549.SGD","LU2746668974.SGD","BK4139","BK4183","IE0009354923.USD","LU2237443978.SGD","UNCY","ODD","IE00BHPRN162.USD","LU0149725797.USD","LU2746668461.USD","LU0971096721.USD","LU2237443382.USD","IE00BZ1G4Q59.USD","CMC","LU2237443622.USD","LU2237443895.HKD","LU0170899867.USD","IE00BKVL7J92.USD","IE00BFXG1179.USD","LU1363072403.SGD","BK4539","LU0882574139.USD","BK4006","LU0267386448.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2606712489","title":"Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712489","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606712489?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607900,"startTime":"0","endTime":"0","summary":"– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3227633/0/en/Immix-Biopharma-Receives-U-S-FDA-Breakthrough-Therapy-Designation-for-NXC-201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4109","IE0009354923.USD","BK4230","BK4183","LU2463526074.USD","ASH","ODD","CAR","NXC"],"gpt_icon":0},{"id":"2606151727","title":"Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2606151727","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606151727?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:09","pubTimestamp":1769602148,"startTime":"0","endTime":"0","summary":"Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/01/50184651/radiopharm-theranostics-says-cash-and-cash-equivalents-of-approximately-34-52m-for-or-the-6-months-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4183","RADX","SOC","IE0009354923.USD","BK4213","DSMC","BK4139"],"gpt_icon":0},{"id":"2606715341","title":"Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2606715341","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606715341?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:00","pubTimestamp":1769601600,"startTime":"0","endTime":"0","summary":"Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases. Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026. Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones. RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of the molecule in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins. RAD 101 has received U.S. Food and Drug Administration  Fast Track Designation to expedite the review process and help bring the novel imaging small molecule to the over 300,000 patients diagnosed annually in the U.S. with cerebral metastases. The study is cur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOC","DSMC","IE0009354923.USD","BK4183","BK4213","BK7067","ODD","RAD.AU"],"gpt_icon":0},{"id":"2606550857","title":"Odd Burger Warns of Imminent Cease Trade Order Over Delayed Annual Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2606550857","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606550857?lang=en_us&edition=fundamental","pubTime":"2026-01-28 06:13","pubTimestamp":1769552002,"startTime":"0","endTime":"0","summary":"Odd Burger Corporation ( ($TSE:ODD) ) has shared an announcement. Odd Burger Corporation has warned that it expects to be hit with a failure-to-fil...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/odd-burger-warns-of-imminent-cease-trade-order-over-delayed-annual-filings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/odd-burger-warns-of-imminent-cease-trade-order-over-delayed-annual-filings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","IE0009354923.USD","ODD"],"gpt_icon":0},{"id":"2606787367","title":"Quoin announces submission to Japanese MHLW for ODD for QRX003","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606787367?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:36","pubTimestamp":1769521010,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that following a successful meeting with the Japanese MHLW that it has submitted an application for Orphan D...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-announces-submission-to-japanese-mhlw-for-odd-for-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-announces-submission-to-japanese-mhlw-for-odd-for-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","ODD","BK4139","BK4183","QNRX"],"gpt_icon":0},{"id":"2606782835","title":"Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782835","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782835?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518800,"startTime":"0","endTime":"0","summary":"Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan.  27, 2026  (GLOBE NEWSWIRE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226448/0/en/Intellia-Therapeutics-Announces-FDA-Lift-of-Clinical-Hold-on-MAGNITUDE-2-Phase-3-Clinical-Trial-in-ATTRv-PN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","IND","IE0009354923.USD","BK4535","LU1861559042.SGD","BK4139","BK4183","LU1861558580.USD","NTLA","ATTR","ODD","BK4585","BK4588"],"gpt_icon":0},{"id":"1107142409","title":"LEADS BIOLABS-B (09887): Vilisin™ Granted Orphan Drug Designation (ODD) by European Commission for Treatment of Extrapulmonary Neuroendocrine Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1107142409","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107142409?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:10","pubTimestamp":1769087425,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that on January 22, 2026, the European Commission (EC) issued an executive decision dated January 9, 2026, granting Orphan Drug Designation (ODD) to the PD-L1/4-1BB...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","IE0009354923.USD","HK0000252160.HKD","BK4183","ODD","09887","BK1161","HK0000252152.HKD"],"gpt_icon":0},{"id":"2604311804","title":"Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen","url":"https://stock-news.laohu8.com/highlight/detail?id=2604311804","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604311804?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:36","pubTimestamp":1768912563,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics (DYN) announced that the Ministry of Health, Labour and Welfare, MHLW, in Japan has granted Orphan Drug designation, ODD, for zel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyne-announces-mhlw-in-japan-granted-odd-for-zeleciment-basivarsen-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyne-announces-mhlw-in-japan-granted-odd-for-zeleciment-basivarsen-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","DYN","BK4505","BK4183","ODD","BK4139","IE0009354923.USD"],"gpt_icon":0},{"id":"2604538401","title":"Insider-Favored Growth Stocks To Consider In January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604538401","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604538401?lang=en_us&edition=fundamental","pubTime":"2026-01-20 01:06","pubTimestamp":1768842365,"startTime":"0","endTime":"0","summary":"As the U.S. stock market grapples with rising Treasury yields and a cautious Federal Reserve outlook, investors are keenly observing growth companies where insiders have significant ownership stakes. In such uncertain times, stocks with high insider ownership can signal confidence in the company's long-term prospects, making them an intriguing consideration for those navigating today's complex market landscape.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-tpc/tutor-perini/news/insider-favored-growth-stocks-to-consider-in-january-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-tpc/tutor-perini/news/insider-favored-growth-stocks-to-consider-in-january-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0719512351.SGD","STUB","IE0009354923.USD","BK4588","LU2931357623.SGD","NIU","LU2290526834.HKD","LU0082616367.USD","LU0274383776.USD","BK4129","LU2065171402.SGD","ODD","BK4558","BK4585","BK7136","LU2360107168.USD","LU2065169927.USD","LU2065170008.USD","SES","BK4096","BK4023","BK4108","LU0053671581.USD","TPC","BK4603","BK4007","BK4595","LU1861215975.USD","BK4091","BK4141","BTDR","LU0566484027.USD","PROP","BK4532","GBFH","BK4555","BK4192","CWBC","CORT","LU2065171311.SGD","SMCI","BK4600","BK4170","BK4211","LU2089985449.USD","BK4543","LU1559883803.SGD","LU1861220033.SGD","BK4183","BK4213"],"gpt_icon":1},{"id":"2604450789","title":"Assessing Oddity Tech (ODD) Valuation After Analyst Praise And METHODIQ Skincare Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2604450789","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604450789?lang=en_us&edition=fundamental","pubTime":"2026-01-17 12:29","pubTimestamp":1768624166,"startTime":"0","endTime":"0","summary":"Oddity Tech (NasdaqGM:ODD) is back in focus after an influential analyst highlighted its recent skincare launch, METHODIQ, along with consistent revenue growth and EBITDA margins near 20%, which has helped lift investor interest in the stock.\nSee our latest analysis for Oddity Tech.\nAt a share price of $35.34, Oddity Tech has seen a 4.56% 1 day share price return, but weaker 30 day and 90 day share price returns of 16.34% and 30.50%, with a 1 year total shareholder return of 19.39%. This...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/assessing-oddity-tech-odd-valuation-after-analyst-praise-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/assessing-oddity-tech-odd-valuation-after-analyst-praise-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4543","NPL.SI","IE0009354923.USD","BK4601","BK4528","BK4551","ETH","BK4588","BK6100","BK4587","BK4585","BK4023","ODD","BK4183","AI"],"gpt_icon":0},{"id":"2603934843","title":"Odd Burger Delays Annual Filings After Financing Default Triggers Liquidity Crunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2603934843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603934843?lang=en_us&edition=fundamental","pubTime":"2026-01-16 07:38","pubTimestamp":1768520309,"startTime":"0","endTime":"0","summary":"Odd Burger Corporation ( ($TSE:ODD) ) has issued an announcement. Odd Burger Corporation has warned that it will miss the January 28, 2026 deadline...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/odd-burger-delays-annual-filings-after-financing-default-triggers-liquidity-crunch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/odd-burger-delays-annual-filings-after-financing-default-triggers-liquidity-crunch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2603524582","title":"ODDITY Tech Secures Expanded $350 Million Credit Facilities to Fund Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2603524582","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603524582?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:47","pubTimestamp":1768258077,"startTime":"0","endTime":"0","summary":"The latest update is out from ODDITY Tech Ltd. Class A ( ($ODD) ). On January 12, 2026, ODDITY Tech Ltd. disclosed that it has amended its existing...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-secures-expanded-350-million-credit-facilities-to-fund-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-secures-expanded-350-million-credit-facilities-to-fund-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","IE0009354923.USD","BK4183"],"gpt_icon":0},{"id":"2603216885","title":"Oddity Tech Ltd: Co Has Entered Into Amendments to Existing Agreements With Syndicate of Banks to Secure Credit Facilities for Total of $350 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2603216885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603216885?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:21","pubTimestamp":1768256515,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD1S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009354923.USD","BK4183","ODD"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":114,"code":"91000000","status":"200"}]}}